Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Pharmacokinetics of ß-d-N4-hydroxycytidine, the active metabolite of prodrug molnupiravir, in non-plasma compartments of patients with SARS-CoV-2 infection

Richard FitzGerald, Laura Dickinson, Laura Else, Thomas Fletcher, Colin Hale, Alieu Amara, Lauren Walker, Sujan Dilly Penchala, Rebecca Lyon, Victoria Shaw, William Greenhalf, Lara Lavelle-Langham, Helen Reynolds, Wendy Painter, Wayne Holman, Sean Ewings, Gareth Griffiths, Saye Khoo
doi: https://doi.org/10.1101/2021.12.06.21267342
Richard FitzGerald
1Liverpool University Hospital NHS Foundation Trust, Liverpool, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura Dickinson
2University of Liverpool, Liverpool, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: laurad@liverpool.ac.uk
Laura Else
2University of Liverpool, Liverpool, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Fletcher
3Liverpool School of Tropical Medicine, Liverpool, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Colin Hale
1Liverpool University Hospital NHS Foundation Trust, Liverpool, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alieu Amara
2University of Liverpool, Liverpool, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lauren Walker
1Liverpool University Hospital NHS Foundation Trust, Liverpool, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sujan Dilly Penchala
2University of Liverpool, Liverpool, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rebecca Lyon
1Liverpool University Hospital NHS Foundation Trust, Liverpool, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Victoria Shaw
2University of Liverpool, Liverpool, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William Greenhalf
2University of Liverpool, Liverpool, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lara Lavelle-Langham
2University of Liverpool, Liverpool, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helen Reynolds
2University of Liverpool, Liverpool, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wendy Painter
4Ridgeback Biotherapeutics, Miami, FL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wayne Holman
4Ridgeback Biotherapeutics, Miami, FL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sean Ewings
5NIHR Southampton Clinical Trials Unit, University of Southampton, Southampton, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gareth Griffiths
5NIHR Southampton Clinical Trials Unit, University of Southampton, Southampton, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Saye Khoo
1Liverpool University Hospital NHS Foundation Trust, Liverpool, UK
2University of Liverpool, Liverpool, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background Molnupiravir, an orally administered prodrug of the broadly active, direct-acting antiviral, ribonucleoside analogue ß-d-N4-hydroxycytidine (NHC) is a promising COVID-19 drug candidate. We characterised the pharmacokinetics of NHC in saliva, nasal secretions and tears of patients enrolled in the phase I AGILE trial (NCT04746183) to understand its potential in preventing infection and transmission.

Methods Patients with PCR-confirmed SARS-CoV-2 infection, within 5 days of symptom onset with mild-to-moderate disease were randomised to oral molnupiravir 300, 600 or 800 mg twice daily or placebo. Plasma and non-plasma (saliva, nasal secretions and tears) samples were collected at pre-dose, 0.5, 1, 2, and 4 hours post-dose on study days 1 and 5 and molnupiravir and NHC measured by LC/MS with a lower limit of quantification of 2.5 ng/mL in all matrices. Pharmacokinetic parameters were determined by noncompartmental methods and non-plasma:plasma ratios (RNP:P; based on AUC0-4) calculated.

Results Twelve participants (n=4 per dosing arm; 75% female) completed the study. NHC Tmax ranged between 1.00-4.00 hours for saliva (n=21) and nasal swabs (n=22) and 0.50-4.00 hours (n=17) for tears compared to 1.00-2.00 hours for plasma (n=19). Median (range) saliva RNP:P pooled across doses was 0.03 (0.01-0.11); n=16. RNP:P for nasal secretions and tears were 0.21 (0.05-0.73); n=17 and 0.22 (0.09-1.05); n=12, respectively. Non-plasma and plasma concentrations were significantly correlated (p<0.0001).

Conclusion These data provide encouraging information regarding the distribution of NHC at sites of viral transmission and have important implications for prophylactic coverage.

Competing Interest Statement

SK has received research funding from ViiV Healthcare, Gilead Sciences, and Merck for the Liverpool HIV Drug Interactions programme and for clinical studies unrelated to the submitted work. GG has received funding from Jannsen-Cilag, Novartis, Astex, Roche, Heartflow, Bristol Myers Squibb, BioNtech; grants and personal fees from AstraZeneca; and personal fees from Celldex, unrelated to the submitted work. WG has received funding from the Wellcome Trust. WH is a cofounder, owner and advisor of/to Ridgeback Biotherapeutics. WP is employed by Ridgeback Biotherapeutics.

Clinical Trial

NCT04746183

Funding Statement

This work was funded by the University of Liverpool. The AGILE platform infrastructure is supported by the Medical Research Council (grant number MR/V028391/1) and the Wellcome Trust (grant number 221590/Z/20/Z). AGILE CST-2 molnupiravir trial was supported by Ridgeback Biotherapeutics. We acknowledge National Institute for Health Research (NIHR) infrastructure funding for the Liverpool Clinical Research Facility and the Southampton Clinical Trials Unit.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the UK Medicines and Healthcare product Regulatory Agency (MHRA; EudraCT 2020 001860 27) and West Midlands Edgbaston Research Ethics Committee (20/WM/0136) and all individuals provided written informed consent.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data analysed and presented in the manuscript are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted December 07, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Pharmacokinetics of ß-d-N4-hydroxycytidine, the active metabolite of prodrug molnupiravir, in non-plasma compartments of patients with SARS-CoV-2 infection
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Pharmacokinetics of ß-d-N4-hydroxycytidine, the active metabolite of prodrug molnupiravir, in non-plasma compartments of patients with SARS-CoV-2 infection
Richard FitzGerald, Laura Dickinson, Laura Else, Thomas Fletcher, Colin Hale, Alieu Amara, Lauren Walker, Sujan Dilly Penchala, Rebecca Lyon, Victoria Shaw, William Greenhalf, Lara Lavelle-Langham, Helen Reynolds, Wendy Painter, Wayne Holman, Sean Ewings, Gareth Griffiths, Saye Khoo
medRxiv 2021.12.06.21267342; doi: https://doi.org/10.1101/2021.12.06.21267342
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Pharmacokinetics of ß-d-N4-hydroxycytidine, the active metabolite of prodrug molnupiravir, in non-plasma compartments of patients with SARS-CoV-2 infection
Richard FitzGerald, Laura Dickinson, Laura Else, Thomas Fletcher, Colin Hale, Alieu Amara, Lauren Walker, Sujan Dilly Penchala, Rebecca Lyon, Victoria Shaw, William Greenhalf, Lara Lavelle-Langham, Helen Reynolds, Wendy Painter, Wayne Holman, Sean Ewings, Gareth Griffiths, Saye Khoo
medRxiv 2021.12.06.21267342; doi: https://doi.org/10.1101/2021.12.06.21267342

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (269)
  • Allergy and Immunology (549)
  • Anesthesia (134)
  • Cardiovascular Medicine (1747)
  • Dentistry and Oral Medicine (238)
  • Dermatology (172)
  • Emergency Medicine (310)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (653)
  • Epidemiology (10780)
  • Forensic Medicine (8)
  • Gastroenterology (584)
  • Genetic and Genomic Medicine (2933)
  • Geriatric Medicine (286)
  • Health Economics (531)
  • Health Informatics (1918)
  • Health Policy (833)
  • Health Systems and Quality Improvement (743)
  • Hematology (290)
  • HIV/AIDS (627)
  • Infectious Diseases (except HIV/AIDS) (12496)
  • Intensive Care and Critical Care Medicine (684)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (321)
  • Neurology (2780)
  • Nursing (150)
  • Nutrition (431)
  • Obstetrics and Gynecology (554)
  • Occupational and Environmental Health (597)
  • Oncology (1454)
  • Ophthalmology (440)
  • Orthopedics (172)
  • Otolaryngology (255)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (379)
  • Pediatrics (865)
  • Pharmacology and Therapeutics (362)
  • Primary Care Research (333)
  • Psychiatry and Clinical Psychology (2630)
  • Public and Global Health (5338)
  • Radiology and Imaging (1002)
  • Rehabilitation Medicine and Physical Therapy (594)
  • Respiratory Medicine (722)
  • Rheumatology (329)
  • Sexual and Reproductive Health (288)
  • Sports Medicine (278)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (149)
  • Urology (125)